RespireRx Pharmaceuticals Inc (RSPI)

[galexa10]

Regarding ADHD and CX-717 -- does the experience and success we had with that AMPAKINE pre/post FDA rejection due to artifact - hold any value for the marketing of CX-1739 for ADHD? My novice take on this is/was somewhat positive. As I remember, CX-717 was ultimately rejected due to the artifact, but didn't COR ultimately show that the anamoly was due to the processing of the samples and not CX-717? Although many argued one way or the other with regards to the FDA decision -- wouldn't CX-1739 (although untested) carry many of the benefits CX-717 already proved to have? Can this story be sold by COR and considered by Big Pharmas, or does the rejection have the opposite implication?